Radionuclide Therapy With 177Lu-PSMA in a Case of Metastatic Adenoid Cystic Carcinoma of the Parotid

Clin Nucl Med. 2019 Sep;44(9):764-766. doi: 10.1097/RLU.0000000000002645.

Abstract

In vivo prostate-specific membrane antigen (PSMA) overexpression creates an opportunity for PSMA-directed theranostic approach in adenoid cystic carcinoma of the parotid. Herein, we illustrate a patient with metastatic PSMA-directed theranostic approach in adenoid cystic carcinoma of the parotid who had intense PSMA uptake on metastatic lesions, followed by radionuclide therapy with Lu-PSMA.

Publication types

  • Case Reports

MeSH terms

  • Carcinoma, Adenoid Cystic / metabolism
  • Carcinoma, Adenoid Cystic / pathology*
  • Carcinoma, Adenoid Cystic / radiotherapy*
  • Female
  • Glutamate Carboxypeptidase II / therapeutic use*
  • Humans
  • Lutetium / therapeutic use*
  • Middle Aged
  • Neoplasm Metastasis
  • Parotid Neoplasms / metabolism
  • Parotid Neoplasms / pathology*
  • Parotid Neoplasms / radiotherapy*
  • Radioisotopes / therapeutic use*

Substances

  • Radioisotopes
  • Lutetium
  • Lutetium-177
  • Glutamate Carboxypeptidase II